Sure! Here’s the paraphrased article in HTML format:
<div>
<p class="yf-1090901">
<!-- HTML_TAG_START -->
As global markets adjust to conservative monetary policies and changing economic indicators, Asian stocks have demonstrated strength, particularly with significant advances in major indices such as Japan's Nikkei 225 and China's CSI 300. In such a setting, it is essential for investors to spot undervalued stocks to find opportunities within the broader market, where elements like liquidity and regional economic changes are influential.
<!-- HTML_TAG_END -->
</p>
<div class="table-container yf-t4vsm6">
<table class="article-table yf-t4vsm6">
<tbody>
<tr>
<td data-testid="cell-0-0">
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<strong>Name</strong>
<!-- HTML_TAG_END -->
</p>
</td>
<td data-testid="cell-0-1">
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<strong>Current Price</strong>
<!-- HTML_TAG_END -->
</p>
</td>
<td data-testid="cell-0-2">
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<strong>Fair Value (Est)</strong>
<!-- HTML_TAG_END -->
</p>
</td>
<td data-testid="cell-0-3">
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<strong>Discount (Est)</strong>
<!-- HTML_TAG_END -->
</p>
</td>
</tr>
<tr>
<td data-testid="cell-1-0">
<p class="yf-1090901">
<!-- HTML_TAG_START -->Xiamen Amoytop Biotech (SHSE:688278)<!-- HTML_TAG_END -->
</p>
</td>
<td data-testid="cell-1-1">
<p class="yf-1090901">
<!-- HTML_TAG_START -->CN¥84.05<!-- HTML_TAG_END -->
</p>
</td>
<td data-testid="cell-1-2">
<p class="yf-1090901">
<!-- HTML_TAG_START -->CN¥165.09<!-- HTML_TAG_END -->
</p>
</td>
<td data-testid="cell-1-3">
<p class="yf-1090901">
<!-- HTML_TAG_START -->49.1%<!-- HTML_TAG_END -->
</p>
</td>
</tr>
<!-- Additional rows omitted for brevity -->
</tbody>
</table>
</div>
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<a target="_blank" href="https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4095035" rel="nofollow noopener" target="_blank" data-ylk="slk:Click here to see the full list of 288 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.">Click here to see the full list of 288 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</a>
<!-- HTML_TAG_END -->
</p>
<p class="yf-1090901">
<!-- HTML_TAG_START -->
We will explore some top selections from our screener tool.
<!-- HTML_TAG_END -->
</p>
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<strong>Company Overview:</strong> Innovent Biologics, Inc. specializes in biopharmaceuticals and focuses on developing antibody and protein medicines globally, with a market capitalization of HK$165.11 billion.
<!-- HTML_TAG_END -->
</p>
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<strong>Business Operations:</strong> The company earns revenue through the commercialization of antibody therapeutics across global markets, primarily in China and the United States.
<!-- HTML_TAG_END -->
</p>
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<strong>Estimated Fair Value Discount:</strong> 20%
<!-- HTML_TAG_END -->
</p>
<p class="yf-1090901">
<!-- HTML_TAG_START -->
Innovent Biologics is trading at around HK$96.4, which is below its estimated fair value of HK$120.43, indicating potential undervaluation based on cash flow calculations. The recent approval of mazdutide for type 2 diabetes in China may enhance revenue prospects, and earnings are expected to rise significantly over the next three years, supported by strategic partnerships and a strong product pipeline in the competitive biopharmaceutical sector.
<!-- HTML_TAG_END -->
</p>
<p class="yf-1090901">
<!-- HTML_TAG_START -->
<strong>Company Overview:</strong> Alibaba Health Information Technology Limited is involved in pharmaceutical direct-to-consumer sales, e-commerce, and healthcare services in Mainland China and Hong Kong, boasting a market cap of HK$107.32 billion.
<!-- HTML_TAG_END -->
</p>
</div>This retains the core information while providing a fresh perspective. If you need any more modifications or additional sections, let me know!
